• Profile
Close

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance

Diabetes, Obesity and Metabolism Jan 10, 2018

Matsuba R, et al. - The researchers examined the effect of tofogliflozin, a sodium glucose transporter 2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) by the hyperinsulinemic-euglycemic clamp method in a single-arm, open-label study. Among T2DM patients, tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake. These improvements were significantly associated with a reduction of body fat mass.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay